All In MedTech

Device Trial Radar · NCT02087501

HORIZON CE Pivotal Study to Treat Abdominal Aortic Aneurysm

A Prospective Open-label Non-randomized Pivotal Study to Evaluate the Safety and Performance of the Horizon™ Abdominal Aortic Aneurysm (AAA) Stent Graft System

Last checked: Nov 20, 2026Latest source record: Dec 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

30

Actual

Start

Apr 2014

Primary completion

Apr 2015

Study completion May 2021

Sponsor

Lead sponsor
Endospan Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Mar 14, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clinical Investigation Design A prospective, open-label, non-randomized, interventional clinical study, sponsored by Endospan Ltd. Patients will be followed-up for five years. Investigational Device The Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System. Purpose The purpose of the study is to evaluate the safety and performance of the Horizon™ AAA Stent Graft System for the treatment of infrarenal abdominal aortic and/or aortoiliac aneurysms. The results of this study will be used as supportive data for CE Marking submission in the European Union (EU). Objectives The primary objectives of the study are to evaluate the safety and performance of the Horizon™ AAA Stent graft System. Primary End Points Safety endpoints include proportion of patients free from device related Major Adverse Events (MAEs) within 1 month of the endovascular procedure. Performance endpoints include successful delivery and deployment of the device; and absence of the following at 1 month follow-up: aneurysm growth ≥5mm, type I or III endoleaks, stent graft occlusion, conversion to open surgery, rupture and stent graft migration. Subject population Thirty (30) patients having infrarenal abdominal aortic and/or aortoiliac aneurysms, having Iliac/femoral access vessel morphology that is compatible with vascular access techniques and devices. Treatment All patients will be treated by implantation of the Horizon™ Abdominal Aortic Aneurysm Stent graft System.

Conditions

  • Infrarenal Abdominal Aortic Aneurysms
  • Aortoiliac Aneurysms

Interventions

  • Horizon™ Abdominal Aortic Aneurysm Stent Graft SystemDevice

    All patient eligible to undergo stent implantation will receive the Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Endpoint: Major Adverse Events (MAEs)Time frame: 1 month post implantation
  2. Performance EndpointTime frame: 1 month post implant

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Nuovo Ospedale Civile S. Agostino Estense - Chirurgia vascolare

    Modena, Italy

  • Azienda Ospedaliera Arcispedale S. Maria Nuova

    Reggio Emilia, Italy

  • Azienda Ospedaliera Ordine Mauriziano di Torino

    Torino, Italy

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.